Stockscreener 앱 받기
0.07%
시간 외 거래:
Danaher Corp 주식(DHR)의 최신 뉴스
Danaher Corporation (DHR) technical analysisDanaher (NYSE:DHR) - Benzinga
DHR Maintained by Wells Fargo -- Price Target Lowered to $195 - GuruFocus
DHR Maintains Buy Rating -- Price Target Lowered to $236 by TD C - GuruFocus
DHR Maintained by Guggenheim -- Price Target Lowered to $200 - GuruFocus
Danaher Posts Mixed Q2 Results, Outlook for 2027 and Beyond Strengthened, RBC Says - marketscreener.com
TD Cowen cuts Danaher stock price target on bioproduction timing By Investing.com - Investing.com Canada
TD Cowen cuts Danaher stock price target on bioproduction timing - Investing.com
Danaher Q2 2026 Deep Dive: EPS Beats by 4.9%, Revenue Up 6% - AlphaStreet
Can Danaher (DHR) Climb 32.39% to Reach the Level Wall Street Analysts Expect? - Zacks Investment Research
Cepheid to Unveil Third-Generation GeneXpert® System at ADLM 2026, Advancing Molecular Diagnostic Capabilities - PR Newswire
Deutsche Bank Adjusts Danaher Price Target to $240 From $250, Maintains Buy Rating - marketscreener.com
Guggenheim cuts Danaher stock price target to $200 on bioprocessing concerns - Investing.com Canada
Danaher Stock Fell 11% After Earnings. Here’s What Could Drive It in 2026 - TIKR.com
Stifel cuts Danaher stock price target on bioprocess weakness By Investing.com - Investing.com Canada
Danaher (NYSE:DHR) Returns To Value Stock Focus After Results Update - Kalkine Media
Danaher revenue up 5.5% to USD 6.3B in Q2 2026 - Medical Buyer
Danaher Shares Drop 11% After Biotech Division Growth Falls Short of Expectations, Forcing Valuation Adjustment - TechStock²
Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com
Wells Fargo Adjusts Price Target on Danaher to $195 From $212, Maintains Equalweight Rating - marketscreener.com
Danaher (DHR) Experiences Significant Decline - GuruFocus
Danaher Shares Slide 11% as Valuation Drops Following Biotech Growth Miss - TechStock²
Guggenheim Adjusts Price Target on Danaher to $200 From $235, Maintains Buy Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Danaher to $210 From $230, Maintains Buy Rating - marketscreener.com
Danaher (DHR) Reports Q3 Revenue Growth of 2%-3% Year-over-Year - GuruFocus
Don’t Quit on Danaher Stock After Horrific Earnings Reaction - Barron's
Key facts: Danaher strong cash; trims 2026 outlook; bio orders, $100M deferred - TradingView
DHR SWOT Analysis: Strong Financials Amidst Competitive Challenges Revealed in 10-Q Filing - GuruFocus
Danaher (DHR) Reports Strong Q2 Earnings, Stock Drops Due to Ord - GuruFocus
Danaher (DHR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Danaher Earnings Call Signals Growing Core Momentum - TipRanks
Danaher (DHR) Reports Strong Q2 2026 Results and Raises EPS Guid - GuruFocus
Danaher Corporation’s Stock Price Plummets to $179.01, Registering a Sharp 10.99% Drop - Smartkarma
Is Danaher Corp (DHR) a Bargain After 11.0% Drop? GF Value Says Undervalued - GuruFocus
Danaher (DHR) Experiences Notable Decline Amid Market Fluctuatio - GuruFocus
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet - Investor's Business Daily
Danaher (DHR) Reports Strong Q2 Earnings, Raises Full-Year Guida - GuruFocus
Danaher Posts Strong Q2 Results Driven By Life Sciences And Masimo Acquisition - insights.citeline.com
Danaher Corporation Provides Revenue Guidance for the Third Quarter 2026 - marketscreener.com
Why Danaher (DHR) Shares Are Falling Today - Yahoo Finance
Danaher (NYSE:DHR) in Focus on A Heavy Earnings Day For Healthcare - Kalkine Media
RBC Raises Danaher Price Target to $215 From $200 - marketscreener.com
Danaher Corp (DHR) Q2 2026 Earnings Call Highlights: Strong Reve - GuruFocus
Danaher Earnings Beat Estimates. Why the Stock Is Dropping Most Since 1991. - Barron's
Danaher stock stabilizes as diagnostics and life sciences support long term growth - Ad-hoc-news.de
Danaher beats Q2 earnings estimates but shares drop on biotech revenue worries - Pluang
Danaher plunges 13% on revenue outlook cut - Breakingthenews.net
Danaher's revenue outlook cut, biotech miss overshadow profit forecast lift - TradingView
DHR: Analyst Consensus Reaches $8.50 for Danaher Corporation - GuruFocus
Evercore ISI Adjusts Price Target on Danaher to $205 From $230 - marketscreener.com
Danaher Q2 Earnings Review: Nothing Exciting For Me To Buy This Dip (NYSE:DHR) - Seeking Alpha
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y - TradingView
Danaher slides as trimmed sales outlook outweighs Q2 beat - Quiver Quantitative
Danaher Q2 2026 Earnings Call Transcript - MarketBeat
Earnings live: Danaher stock plunges on trimmed forecast, 3M stock surges - Yahoo Finance
Danaher's Momentum May Stall in Late 2026 on Bioprocessing Customer Delays - Morningstar
Danaher Lifts Full-Year Profit Outlook Following Second-Quarter Beat, Tempers Sales Guidance - marketscreener.com
Danaher (NYSE:DHR) stock drops 14% as bioprocessing gap clouds outlook - TechStock²
Danaher reports $870M Q2 2026 net earnings and raises guidance - grafa.com
Why Danaher Stock Just Tanked 14% - Benzinga
Danaher (DHR) Reports Strong Q2 Earnings, Raises Full Year Guida - GuruFocus
Danaher Edges Past Q2 2026 Estimates, Posts $1.94 EPS, Revenue Up 6% - AlphaStreet
Transcript: Danaher Q2 2026 Earnings Conference Call - Benzinga
Earnings call transcript: Danaher beats Q2 2026 estimates but shares sink - Investing.com
Danaher Q2 2026 slides show mixed results as stock tumbles 15% - Investing.com
Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Danaher Corporation 2026 Q2ResultsEarnings Call Presentation (NYSE:DHR) 2026-07-21 - Seeking Alpha
Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook - Bitget
Danaher (DHR) Q2 2026 earnings summary - Quartr
0.57%
1.35%
자본화:
|
볼륨(24시간):